Acute venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), are the most common preventable causes of hospital death and a source of substantial long-term morbidity. The impact on health is so great that the Surgeon General…
You’re Reading a Preview Become a Clinical Tree membership for Full access and enjoy Unlimited articles Become membership If you are a member. Log in here
There are many pharmacologic options in current use to treat and prevent venous thromboembolism (VTE). These medications include unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), factor Xa inhibitors (anti-Xa drugs), direct thrombin inhibitors (anti-IIa drugs), and vitamin K antagonists. UFH and…
Venous thromboembolism (VTE) is a significant national health problem, with approximately 900,000 individuals affected annually. When compared with whites, African Americans have a 40% higher incidence of VTE. Despite improvements in prophylaxis and treatment of VTE, the incidence of this…
Procoagulant states may be divided into acquired and genetic causes. Acquired factors include advanced age, obesity, malignancy, surgery, prolonged immobilization, use of estrogens, antiphospholipid syndrome (APS), heparin-induced thrombocytopenia and thrombosis (HITT), and pregnancy. Genetic conditions include male gender, antithrombin III…